HUP0103319A2 - Készítmények HIV- és egyéb vírusfertőzések kezelésére és alkalmazásuk - Google Patents

Készítmények HIV- és egyéb vírusfertőzések kezelésére és alkalmazásuk

Info

Publication number
HUP0103319A2
HUP0103319A2 HU0103319A HUP0103319A HUP0103319A2 HU P0103319 A2 HUP0103319 A2 HU P0103319A2 HU 0103319 A HU0103319 A HU 0103319A HU P0103319 A HUP0103319 A HU P0103319A HU P0103319 A2 HUP0103319 A2 HU P0103319A2
Authority
HU
Hungary
Prior art keywords
treatment
viral infections
hiv
compositions
hydrogen atom
Prior art date
Application number
HU0103319A
Other languages
English (en)
Inventor
James Berger Camden
Original Assignee
The Procter & Gamble Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Procter & Gamble Co. filed Critical The Procter & Gamble Co.
Publication of HUP0103319A2 publication Critical patent/HUP0103319A2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A találmány tárgyát egy vagy több általános képletű benzimidazolt -ahol előnyösen X hidrogén- vagy halogénatom, alkil- vagyalkoxicsoport; n értéke 0-3; Y hidrogénatom; R hidrogénatom vagyalkilcsoport; és R2 4-tiazolil-csoport vagy sóját, elsősorbantiabendazolt, valamint adott esetben más típusú antivirálishatóanyagot tartalmazó gyógyszerkészítmények, továbbá vírusfertőzések,különösen HIV-fertőzések kezelésére szolgáló eljárások képezik. Ó
HU0103319A 1998-05-19 1999-05-19 Készítmények HIV- és egyéb vírusfertőzések kezelésére és alkalmazásuk HUP0103319A2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8138498A 1998-05-19 1998-05-19

Publications (1)

Publication Number Publication Date
HUP0103319A2 true HUP0103319A2 (hu) 2002-05-29

Family

ID=22163807

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103319A HUP0103319A2 (hu) 1998-05-19 1999-05-19 Készítmények HIV- és egyéb vírusfertőzések kezelésére és alkalmazásuk

Country Status (19)

Country Link
US (1) US6245789B1 (hu)
EP (1) EP1079831A1 (hu)
JP (1) JP2002515432A (hu)
KR (1) KR20010043709A (hu)
CN (1) CN1301158A (hu)
AR (1) AR019305A1 (hu)
AU (1) AU4004299A (hu)
BR (1) BR9911043A (hu)
CA (1) CA2329877A1 (hu)
CO (1) CO5050303A1 (hu)
HU (1) HUP0103319A2 (hu)
ID (1) ID27457A (hu)
IL (1) IL139002A0 (hu)
NO (1) NO20005839L (hu)
PE (1) PE20000550A1 (hu)
PL (1) PL344223A1 (hu)
SK (1) SK17442000A3 (hu)
TR (1) TR200003383T2 (hu)
WO (1) WO1999059585A1 (hu)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6242461B1 (en) * 2000-01-25 2001-06-05 Pfizer Inc. Use of aryl substituted azabenzimidazoles in the treatment of HIV and AIDS related diseases
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
AU2002239395A1 (en) * 2000-11-01 2002-06-03 The Procter And Gamble Company Hiv treatment with benzimidazoles
ES2245380T3 (es) 2000-12-15 2006-01-01 Glaxo Group Limited Pirazolopiridinas.
WO2002048148A2 (en) 2000-12-15 2002-06-20 Glaxo Group Limited Pyrazolopyridine derivatives
JP2004529119A (ja) 2001-03-08 2004-09-24 スミスクライン ビーチャム コーポレーション ピラゾロピリジン誘導体
JP4237497B2 (ja) 2001-03-30 2009-03-11 スミスクライン ビーチャム コーポレーション ピラゾロピリジン類、その調製方法及びその治療用化合物としての使用
JP4219171B2 (ja) 2001-04-10 2009-02-04 スミスクライン ビーチャム コーポレーション 抗ウイルス性ピラゾロピリジン化合物
DE60204452T2 (de) 2001-04-27 2005-12-15 Smithkline Beecham Corp. Pyrazolo[1,5a]Pyridinderivate
US7186714B2 (en) 2001-06-21 2007-03-06 Smithkline Beecham Corporation Imidazo[1,2-α]pyridine derivatives for the prophylaxis and treatment of herpes viral infections
ES2262893T3 (es) 2001-10-05 2006-12-01 Smithkline Beecham Corporation Derivados de imidazo-piridina para su uso en el tratamiento de infeccion virica por herpes.
JP2005516916A (ja) * 2001-12-11 2005-06-09 スミスクライン ビーチャム コーポレーション 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
AU2003220585A1 (en) * 2002-03-26 2003-10-13 Arizona Board of Regents on behalf of the University of Arizone Solubilization of weak bases
EP1546148A1 (en) 2002-10-03 2005-06-29 SmithKline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
AU2003900064A0 (en) * 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
JP2005060362A (ja) * 2003-07-28 2005-03-10 Shionogi & Co Ltd セスキテルペン誘導体を含有する抗HIV剤、抗BVDV剤、抗HCV剤又は抗CoV剤
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
US9655962B2 (en) * 2013-03-15 2017-05-23 Camas Incorporated Methods and compositions for reducing microorganisms in the oropharynx, nasopharynx and oral cavities
FR3057865A1 (fr) * 2016-10-21 2018-04-27 Laboratoire Michel Iderne Composition chimique
TW201936193A (zh) * 2017-12-05 2019-09-16 愛爾蘭商健生科學愛爾蘭無限公司 使用組合產品治療rsv
KR102342313B1 (ko) * 2021-08-27 2021-12-24 (주)바이오메트릭스 테크놀로지 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3010968A (en) 1959-11-25 1961-11-28 Du Pont Process for manufacture of certain alkyl esters of benzimidazole carbamic acids
NL134354C (hu) 1963-05-23
US3499761A (en) 1964-07-20 1970-03-10 Gaf Corp Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents
US3541213A (en) 1966-05-06 1970-11-17 Du Pont Fungicidal and mite ovicidal substituted 2-aminobenzimidazoles
US3881014A (en) 1968-11-05 1975-04-29 Bayer Ag N-tritylimidazoles for treating fungal infections
BE759337A (fr) 1969-11-24 1971-05-24 Lilly Co Eli Benzimidazol (2,1-b)-quinazolin (6h) ones qui sont des immuno-depresseurs, et nouvelles benzimidazo (2,1-b) quinazolin-12-(6h) ones
US3956262A (en) 1970-12-09 1976-05-11 Beecham Group Limited Triazenoimidazoles
US3738995A (en) 1971-05-14 1973-06-12 Du Pont Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates
FR2155888A1 (en) 1971-10-13 1973-05-25 Agot Aime Solid anthelmintic composn - for more economical treatment of ruminants
US4046906A (en) 1973-04-21 1977-09-06 Hoechst Aktiengesellschaft Salts of alkyl 2-benzimidazole-carbamate
HU193951B (en) 1985-03-11 1987-12-28 Richter Gedeon Vegyeszet Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them
US4731366A (en) 1986-08-05 1988-03-15 Harbor Branch Oceanographic Institution, Inc. Discorhabdin compositions and their methods of use
GB2210875B (en) 1987-10-09 1991-05-29 Farmos Oy Aromatase inhibiting 4(5)-imidazoles
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
US5114951A (en) 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
US5149527A (en) 1990-09-18 1992-09-22 Oncotech, Inc. Immunopotentiating protocol for chemotherapy-responsive tumors
US5310748A (en) 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
US5364875A (en) 1992-05-11 1994-11-15 The Du Pont Merck Pharmaceutical Company Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
US5290801A (en) 1992-05-29 1994-03-01 The Du Pont Merck Pharmaceutical Company Benzimidazoles for the treatment of atherosclerosis
KR950702994A (ko) 1992-08-12 1995-08-23 로렌스 티. 웰츠 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol)
KR100311551B1 (ko) 1993-03-31 2001-12-28 폴락 돈나 엘. Aids 치료용 약제학적 배합물 중의 hiv 프로테아제 억제제
US5434163A (en) 1993-05-14 1995-07-18 The Medical College Of Pennsylvania Treatment of Cryptococcus neoformans infection
JP3213471B2 (ja) 1994-04-13 2001-10-02 ポーラ化成工業株式会社 薬効成分含有リポソーム製剤の製造方法
US5665713A (en) 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
NZ305784A (en) 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections
ZA962880B (en) 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
ZA962879B (en) 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
US5656615A (en) 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
KR19980703829A (ko) 1995-04-12 1998-12-05 레이셔 야코버스 코넬리스 바이러스 및 암 성장 억제용, 엔-클로로페닐카르바메이트및 엔-클로로페닐티오카르바메이트 함유 약학 조성물
US5629341A (en) 1995-04-12 1997-05-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US5665751A (en) 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
PL324026A1 (en) 1995-06-07 1998-05-11 Procter & Gamble Application of imidazoles in production of a drug designed to treat leukaemia
MX9707809A (es) 1995-06-07 1998-01-31 Procter & Gamble Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres.
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6200992B1 (en) 1995-06-07 2001-03-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
JPH11511136A (ja) 1995-08-03 1999-09-28 ザ プロクター アンド ギャンブル カンパニー 癌の成長を阻害するためのグリセオフルビンの使用
MX9800998A (es) 1995-08-04 1998-04-30 Procter & Gamble Uso de fluconazol para inhibir el crecimiento de canceres.
US5908855A (en) 1996-07-16 1999-06-01 The Procter & Gamble Company Compositions for treating viral infections
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
PE11499A1 (es) 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US6506783B1 (en) 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment

Also Published As

Publication number Publication date
CO5050303A1 (es) 2001-06-27
JP2002515432A (ja) 2002-05-28
CN1301158A (zh) 2001-06-27
ID27457A (id) 2001-04-12
NO20005839D0 (no) 2000-11-17
EP1079831A1 (en) 2001-03-07
SK17442000A3 (sk) 2001-08-06
AU4004299A (en) 1999-12-06
CA2329877A1 (en) 1999-11-25
KR20010043709A (ko) 2001-05-25
PE20000550A1 (es) 2000-06-29
PL344223A1 (en) 2001-10-08
NO20005839L (no) 2001-01-16
US6245789B1 (en) 2001-06-12
WO1999059585A1 (en) 1999-11-25
IL139002A0 (en) 2001-11-25
AR019305A1 (es) 2002-02-13
BR9911043A (pt) 2001-02-13
TR200003383T2 (tr) 2001-03-21

Similar Documents

Publication Publication Date Title
HUP0103319A2 (hu) Készítmények HIV- és egyéb vírusfertőzések kezelésére és alkalmazásuk
HUP0100100A2 (hu) Hepatitis C inhibitor peptid-analógok, ezeket hatóanyagként tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0301320A2 (hu) Glikopeptid-foszfonát-származékok
TR200300544T1 (tr) Erimiş siklik bileşimler ve tıbbi kullanımları
HUP0103460A2 (hu) Vírusellenes hatású indolszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények
BR9914221B1 (pt) Derivados de glicopeptídeos e composições farmacêuticas contendo os mesmos
HUP0101999A2 (hu) 4-Hidroxi-kinolin-3-karboxamid- és -hidrazid-származékok, ezeket tartalmazó gyógyászati készítmények, valamint e vegyületek alkalmazása
DE69909756D1 (de) Antivirale pyrimidinderivate
DE60009511D1 (de) Nematizide trifluorbutene
ES2191048T3 (es) Derivados de oxazolidinona y compuestos farmaceuticos que los contienen.
DE60212949D1 (de) Antivirale pyrazolopyridin verbindungen
HUP0302792A2 (hu) Dipeptidil peptidáz ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0202593A2 (hu) Reverz transzkriptáz inhibitor hatású benzofenonok és ilyen vegyületeket tartalmazó gyógyászati készítmények
MY128458A (en) Antiviral azaindole derivatives
GEP20053601B (en) Nucleoside Derivatives as Inhibitors of RNA-Dependent RNA Viral Polymerase
DE60215157D1 (de) Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
NO20061788L (no) HIV-replikasjonshemmede purinderivater
BR0009485A (pt) Método e composições para evitar ou reduzir infecção por hiv pelo uso de inibidores para leucina aminopeptidase
ATE498630T1 (de) Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
DE60211539D1 (de) Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
ATE300541T1 (de) Pyrazolopyridinderivate
NO20040881L (no) Orale antidiabetes midler.
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
ATE233754T1 (de) Diphenyl-piperidin derivate
SE0101038D0 (sv) Novel compounds